For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine) that deliver modest efficacy of limited duration. Understanding today’s treatment landscape is important for emerging players as the heavily generic AD market braces for the potential entry of a variety of new, high-cost brands—namely, landmark disease-modifying therapies and new behavioral adjuncts. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.

Questions Answered

  • What patient share do key therapies and brands garner by line of treatment in newly diagnosed AD patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed AD patients?
  • How has Namzaric been integrated into the AD treatment algorithm?
  • What proportion of AD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of AD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with AD?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Allergan, Novartis

Key drugs: Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine IR, Namenda XR, Namzaric

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Related Reports

Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open th...

View Details

Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantin...

View Details

Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2019

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the oppo...

View Details